Related Experiment Video

Updated: Feb 16, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?

Stephen Philip1, Malika Kumarasiri1, Theodosia Teo1

  • 1Centre for Drug Discovery and Development, Sansom Institute for Health Research and School of Pharmacy and Medical Sciences , University of South Australia , Adelaide , South Australia 5001 , Australia.

Journal of Medicinal Chemistry
|December 22, 2017
PubMed

Insights

Cyclin-dependent kinase 8 (CDK8) is a key driver in many cancers, influencing transcription and signaling pathways. Research explores its dual role and the development of CDK8 inhibitors for cancer therapy.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Biochemistry

Background:

  • Cyclin-dependent kinase 8 (CDK8) regulates gene transcription via Mediator complex association and transcription factor phosphorylation.
  • CDK8 is implicated as an oncogenic driver in various cancers, including colorectal, breast, and hematological malignancies.
  • Its roles in oncogenesis involve activating Wnt-β-catenin signaling, regulating estrogen-inducible genes, and suppressing super enhancer-associated genes.

Purpose of the Study:

  • To review the current understanding of CDK8 biology and its role in carcinogenesis.
  • To analyze the conflicting evidence regarding CDK8's function as an oncogene or tumor suppressor.
  • To examine the progress in developing CDK8 inhibitors for cancer treatment and future therapeutic prospects.

Main Methods:

  • Literature review of genetic and biochemical studies on CDK8.
  • Analysis of CDK8's involvement in specific cancer signaling pathways.
  • Survey of current research on CDK8 inhibitor discovery and development.

Main Results:

  • CDK8's established role as an oncogenic driver in multiple cancer types.
  • Emerging evidence suggesting context-dependent or contrary functions of CDK8.
  • Significant interest and controversy surrounding CDK8 inhibitors as cancer therapeutics.

Conclusions:

  • CDK8 exhibits complex and context-specific roles in cancer, necessitating careful consideration for therapeutic targeting.
  • The development of CDK8 inhibitors is a promising but challenging area in oncology.
  • Further research is crucial to fully elucidate CDK8's functions and optimize targeted therapies.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.4K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.9K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K